세계의 플러싱 솔루션 시장 : 유형, 용도, 최종사용자, 지역별(-2035년)

Global Flushing Solution Market Research Report by Type (Saline-Based Solutions, Heparin-Based Solutions, Others), by Application (Gastrointestinal Procedures, Urinary Flushing, Vascular Flushing, Others), by End User (Hospitals and Specialty Clinics, Ambulatory Surgical Centers, Research Laboratories & Institutes), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2035

Industry Overview

The global flushing solution market will nearly double from USD 1,116.05 million in 2024 to USD 2,214.96 million in 2035 and expand at a CAGR of 6.59% by the forecast year. Flushing solutions are specially made sterile fluids that are used to keep medical devices working properly and safe during a procedure. They are an important part in opening devices that have been blocked, keeping them patent, and also reducing the chances of infection in catheters, IV lines, or any other devices for access. Patients can find doctors using saline and heparinized saline, as these are the most popular types of solutions.

Growing reliance on diagnostic procedures like colonoscopies and endoscopies is significantly fueling the Global Flushing Solution Market. Rising gastrointestinal disease cases, including cancers and chronic conditions, underscore the importance of accurate screenings. Flushing solutions ensure device patency, patient comfort, and effective preparation of the tract during these procedures. Supported by technological innovations and heightened awareness of preventive healthcare, demand for specialized solutions will accelerate globally over the next decade.

Key Company Development

Pentaferte Italia took a significant step forward in November 2023 by entering a distribution partnership with Medline Europe, expanding the reach of its sterile pre-filled syringe portfolio. Designed for vascular flushing procedures, these syringes come pre-filled with 0.9% saline solution (NaCl), ensuring reliability and reducing preparation time in clinical workflows. The partnership highlights Pentaferte's strategy of combining product innovation with strong distribution networks to meet growing demand across Europe. Known for its expertise in high-quality sterile solutions, Pentaferte reinforces its market leadership by offering healthcare professionals a dependable option for flushing both central and peripheral vascular devices. This collaboration with Medline Europe underscores the company's commitment to patient safety, efficiency, and strengthening its footprint in key European healthcare markets.

Key Players

Major players in the global flushing solution market are Becton, Dickson and Company, Baxter, B.Braun SE, Amsino International, Inc., Aquabiliti, Medline Industries, LP, McKesson Corporation, SPM Medicare Pvt. Ltd., Polymedicure, Medefil, Inc., Tianhe Pharmaceutical Co., Ltd, and Pentaferte.

Report Attribute Details

Market Size 2024 USD 1,116.05 Million

Market Size 2035 USD 2,214.96 Million

CAGR (2025-2035) 6.59%

Base Year 2024

Market Forecast Period 2025-2035

Historical Data 2019-2024

Market Segmentations

By Type: Saline-Based Solutions - 6.50%, Heparin-Based Solutions - 7.30%.

By Application: Gastrointestinal Procedures - 7.14%, Urinary Flushing - 6.45%.

By End User: Hospitals and Specialty Clinics - 6.17%, Ambulatory Surgical Centers - 8.02%.

Regional Analysis

The North American flushing solution market benefits from the technological innovations that are being adopted on a large scale and the patient-oriented care models. The United States dominates North America's flushing solution market with USD 385.92 million, while Canada follows with USD 51.90 million, reinforcing the U.S. as the key revenue contributor across the region. Demand for these products is notably high in the United States, and this is linked to the fact currently there are currently prevalent chronic diseases that require long-term intravenous therapy.

Europe is a major player in the world market for flushing solutions. Germany leads at USD 89.27 million, followed by the UK at USD 71.95 million and France at USD 64.06 million, showcasing the strength of Western European markets. The area is witnessing stable demand from the hospital sector, not only from public but also from private institutions, the most notable trend being in Western Europe.

The growth of the Asia Pacific market is driven by urbanization at a fast rate and healthcare infrastructure investments that have been on the rise. China tops the market with USD 73.70 million, while India follows at USD 56.36 million, underscoring their leadership in regional demand. Multinational companies are capitalizing on their presence by collaborating with local distributors.

In regions such as Latin America, the Middle East, and Africa, the flushing solution market is expanding at a moderate pace. Healthcare reforms led by the government in Latin America are beneficial as they increase patient access to modern care solutions. At the same time, the growing emphasis on advanced healthcare practices is making Gulf countries the new attractive markets.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING NUMBER OF DIAGNOSTIC PROCEDURES LIKE COLONOSCOPIES AND ENDOSCOPIES
  • 4.2.2 GROWING PREVALENCE OF KIDNEY STONES
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY REQUIREMENTS
  • 4.3.2 LACK OF AWARENESS IN DEVELOPING REGIONS
• 4.4 OPPORTUNITY
  • 4.4.1 RISING AGING POPULATION
  • 4.4.2 INCREASED ADOPTION OF MINIMALLY INVASIVE PROCEDURES

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL FLUSHING SOLUTION MARKET

6 GLOBAL FLUSHING SOLUTION MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 SALINE-BASED SOLUTIONS
• 6.3 HEPARIN-BASED SOLUTIONS
• 6.4 OTHERS

7 GLOBAL FLUSHING SOLUTION MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 GASTROINTESTINAL PROCEDURES
• 7.3 URINARY FLUSHING
• 7.4 VASCULAR FLUSHING
• 7.5 OTHERS

8 GLOBAL FLUSHING SOLUTION MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS AND SPECIALTY CLINICS
• 8.3 AMBULATORY SURGICAL CENTERS (ASCS)
• 8.4 RESEARCH LABORATORIES & INSTITUTES

9 GLOBAL FLUSHING SOLUTION MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 SPAIN
  • 9.3.5 ITALY
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA,
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST AND AFRICA
  • 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.1.1 PARTNERSHIP

11 COMPANY PROFILES

• 11.1 MCKESSON CORPORATION
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 SPM MEDICARE PVT. LTD.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 POLYMEDICURE
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 MEDEFIL, INC.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 TIANHE PHARMACEUTICAL CO., LTD.
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 PENTAFERTE
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 BECTON, DICKINSON AND COMPANY
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 BAXTER
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 B. BRAUN SE
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 SWOT ANALYSIS
  • 11.9.6 KEY STRATEGIES
• 11.10 AMSINO INTERNATIONAL, INC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES
• 11.11 AQUABILITI
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCT OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 KEY STRATEGIES
• 11.12 MEDLINE INDUSTRIES, LP
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL OVERVIEW
  • 11.12.3 PRODUCT OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 KEY STRATEGIES

12 DATA CITATIONS